Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01009502 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome
A Phase 1 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01009502 is a Phase 1 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 1 participants.
The verdict
NCT01009502, a Phase 1 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
Sodium stibogluconate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This was originally designed as a phase I/II trial studying the side effects of sodium stibogluconate and how well it works in treating patients with myelodysplastic syndromes. Unfortunately, due to funding issues, the phase II portion was never conducted.
Interventions
- DRUG sodium stibogluconate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-07 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01009502
The ClinicalTrials.gov registry entry for NCT01009502 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sodium stibogluconate is the first listed.
NCT01009502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01009502 about?
NCT01009502 is a clinical study titled "Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome". Sodium stibogluconate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This was originally designed as a phase I/II trial studying the side effects of sodium stibogluconate and how well it works in treating patients with myelodysplastic syndromes. Unfortun...
What is the current status of trial NCT01009502?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2009-07. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01009502?
The interventions under investigation include: sodium stibogluconate (DRUG).
Who is sponsoring clinical trial NCT01009502?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.